Premium
Regarding: Humar et al. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients. Am J Transplant 2010;10:1228–1237
Author(s) -
da CunhaBang C.,
Iversen M.,
Mortensen S. A.,
Rasmussen A.,
Sengeløv H.,
Sørensen S. S.,
Lundgren J.
Publication year - 2011
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2010.03349.x
Subject(s) - valganciclovir , medicine , chemoprophylaxis , ganciclovir , cytomegalovirus , foscarnet , kidney transplant , transplantation , kidney transplantation , immunology , human cytomegalovirus , virus , viral disease , herpesviridae